2025 Oncologic Toxicity Management Symposium: Novel Oncology Agents and Adverse Events


2025 Oncologic Toxicity Management Symposium: Novel Oncology Agents and Adverse Events Banner

Add to Calendar 2025 Oncologic Toxicity Management Symposium: Novel Oncology Agents and Adverse Events 6/20/2025 8:00:00 AM 6/20/2025 6:00:00 PM America/New_York For More Details: https://mskcc.cloud-cme.com/course/courseoverview?EID=55968 Description: The 2025 Oncology Toxicity Management Symposium unites leading oncologists, researchers, and healthcare professionals to explore the latest breakthroughs in cancer treatment and toxicity management. With rapid advancements in oncology, this symposium serves as a critical platform for discussing emerging therapies, their clinical applications, and strategies to mitigate treatment-related adverse events,... Zuckerman Research Center, 417 East 68th Street false MM/DD/YYYY


Date & Location
Friday, June 20, 2025, 8:00 AM - 6:00 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY

Specialties
Specialties - Allergy and Immunology, Cardiology, Dermatology, Dermatopathology, Emergency Medicine, Endocrinology, Diabetes and Metabolism, Gastroenterology, Gastrointestinal Oncology, Genitourinary Oncology, Geriatric Medicine, Gynecologic Oncology, Immunotherapy, Integrative Medicine, Medical Oncology, Neurology, Neuro-Oncology, Nurse Practitioner, Rheumatology, Solid Tumor Oncology

Overview

The 2025 Oncology Toxicity Management Symposium unites leading oncologists, researchers, and healthcare professionals to explore the latest breakthroughs in cancer treatment and toxicity management. With rapid advancements in oncology, this symposium serves as a critical platform for discussing emerging therapies, their clinical applications, and strategies to mitigate treatment-related adverse events, ultimately aiming to improve patient care and outcomes.

As oncology continues to evolve, new therapies are revolutionizing the landscape of cancer treatment. This symposium will provide a comprehensive, evidence-based approach to understanding next-generation treatments, their efficacy, and the challenges associated with their implementation in clinical practice.

Attendees will gain deep insights into the mechanisms, benefits, and risks of cutting-edge therapies, including:

  • Radioligand Therapy – A novel approach that delivers targeted radiation to cancer cells, offering precise treatment with minimal damage to surrounding tissues. The session will focus on clinical applications, effectiveness, and strategies to manage radiation-related toxicity.

  • Antibody Drug Conjugates (ADCs) – A breakthrough class of targeted cancer therapies designed to deliver highly potent chemotherapy directly to cancer cells. Experts will discuss the latest ADC developments, clinical benefits, and effective management of associated toxicities.

  • CAR-T Cell Therapy – A groundbreaking immunotherapy that harnesses the body’s own immune system to fight cancer. This session will address treatment protocols and management of adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

  • Bispecific Antibodies – A cutting-edge approach that redirects T-cells to attack tumor cells. Attendees will gain an understanding of the potential of Bispecific Antibodies, their clinical applications, and how to mitigate immune-related toxicities.

  • Small Molecule Inhibitors (SMIs) – Targeted agents that block key pathways involved in cancer growth. This session will explore the role of SMIs in oncology, their therapeutic potential, and management of associated risks such as cardiovascular toxicity and metabolic disturbances.

  • Immune Checkpoint Inhibitors (ICIs) – A revolutionary class of immunotherapies that enhance the body’s natural ability to fight cancer. Experts will discuss how ICIs are reshaping oncology, the challenges of immune-related adverse events (irAEs), and best practices for toxicity management.

Through expert-led presentations, panel discussions, and interactive Q&A sessions, attendees will deepen their understanding of novel therapies transforming oncology care, learn strategies to manage treatment-related toxicities, engage with thought leaders on cutting-edge research and clinical trials, and connect with peers to foster innovation in cancer treatment.

Target Audience

This symposium is an essential event for oncologists, hematologists, researchers, nurse practitioners, physician assistants, pharmacists, and all healthcare professionals involved in cancer care. Attendees will leave with actionable knowledge and practical tools to optimize patient outcomes and stay at the forefront of oncology advancements.


Objectives
At the conclusion of this symposium, attendees will be able to:

  1. Describe the mechanism of action, indications, and clinical efficacy of Radioligand Therapy, Antibody Drug Conjugates (ADCs), Bispecific Antibodies, CAR-T Cell Therapy, Small Molecule Inhibitors (SMIs), and Immune Checkpoint Inhibitors (ICIs).
  2. Develop evidence-based strategies to identify, prevent, and manage treatment-related toxicities, such as cytokine release syndrome (CRS), neurotoxicity, immune-related adverse events (irAEs), and organ-specific toxicities.
  3. Recognize the early signs of adverse reactions and implement effective interventions to reduce complications and improve patient safety.
  4. Apply clinical case studies and expert insights to make informed, patient-centered decisions in oncology treatment planning.
  5. Discuss how to balance treatment efficacy with toxicity management to optimize long-term patient outcomes.

Registration

Discounted registration is available for specific groups. If eligible, you will receive further instructions and a promotion code to use during registration. View our Policy on Registration Discounts for more information.

Registration Fees

  • Physicians (MDs, PhDs, and DOs): $300

  • Advanced Practice Providers: $250

  • Nursing and Other Healthcare Professionals: $200

  • Residents, Fellows, and Students: $100*

  • Industry Professionals**: $525

  • Patients, Advocates, and Caregivers: Complimentary

  • MSK Employees: Complimentary

For details on our cancellation terms, please review our Cancellation Policy.

*Registration fees for residents, fellows, and students are non-refundable.
**An “industry professional” is defined as any individual, regardless of their profession type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company. View our Registration Policy for Industry Professionals for more information.

Continental breakfast, lunch, and refreshment breaks are included with registration. If you have any special dietary needs or require specific accommodations to attend in person, please contact us at [email protected] at least one week prior to the symposium.


Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ANCC CNE Statement

An application for ANCC Nursing Contact Hours has been submitted.